Marker Therapeutics (NASDAQ:MRKR) Trading 3% Higher – Here’s Why

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) shot up 3% during mid-day trading on Monday . The company traded as high as $1.39 and last traded at $1.37. 43,227 shares were traded during trading, a decline of 25% from the average daily volume of 57,638 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

MRKR has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Stock Performance

The firm’s fifty day moving average price is $1.46 and its 200 day moving average price is $1.51. The firm has a market cap of $22.84 million, a P/E ratio of -2.25 and a beta of 1.44.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. As a group, analysts expect that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its position in shares of Marker Therapeutics by 16.5% during the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after buying an additional 13,340 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after acquiring an additional 17,400 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Marker Therapeutics during the 2nd quarter worth approximately $33,000. LPL Financial LLC lifted its position in Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Marker Therapeutics in the third quarter valued at approximately $25,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.